Latest news with #LiisaBayko
Reuters
3 days ago
- Business
- Reuters
Vera shares skyrocket as kidney disease drug succeeds in late-stage trial
June 2 (Reuters) - Shares of Vera Therapeutics (VERA.O), opens new tab soared 82% on Monday, after the company said its experimental drug helped significantly reduce excess levels of harmful proteins in the urine of kidney disease patients in a late-stage study. The drug developer's shares surged to $34.24 in premarket trading, giving it a market value of $2.18 billion, if gains hold. The drug, atacicept, reduced protein levels in the urine by 46% in patients with IgA nephropathy, which was statistically significant compared to a placebo, meeting the main goal of the study, the company said. In IgA nephropathy, there is a buildup of proteins that causes inflammation in kidneys, which is indicated by their presence in the patient's urine. The late-stage study data beat investor's expectations, which were based on the 35% reduction seen in the mid-stage study of the drug, said Evercore ISI analyst Liisa Bayko in a note. Vera plans to submit a marketing application to the FDA in fourth-quarter and expects for potential commercial launch in 2026 in the United States. The study will continue to test the change in kidney function over two years and is expected to complete in 2027. Rival Japan-based firm Otsuka Holdings (4578.T), opens new tab has already filed for a marketing application to the U.S. Food and Drug Administration for its kidney disease drug, sibeprenlimab. That drug is expected to reach the market six to nine months ahead of Vera's atacicept, Bayko said. In a separate mid-stage trial, Otsuka's drug had helped reduce levels of excess proteins by 43%, according to Evercore.
Business Insider
5 days ago
- Business
- Business Insider
Evercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) yesterday and set a price target of $48.00. The company's shares closed yesterday at $7.45. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bayko is a 4-star analyst with an average return of 5.9% and a 40.98% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Altimmune, Vertex Pharmaceuticals, and Intellia Therapeutics. In addition to Evercore ISI, Intellia Therapeutics also received a Buy from JonesTrading's Debanjana Chatterjee in a report issued today. However, yesterday, J.P. Morgan maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA). The company has a one-year high of $28.18 and a one-year low of $5.90. Currently, Intellia Therapeutics has an average volume of 3.83M.
Yahoo
14-02-2025
- Business
- Yahoo
CRISPR Therapeutics Stock Upgrade Following Analyst Reassessment
CRISPR Therapeutics (CRSP, Financials) stock rose 16.4% to $50.60 as of 10:10 a.m. GMT-5 on Friday, following an analyst upgrade. Citing pipeline advancements and possible catalysts, Evercore ISI analyst Liisa Bayko raised CRISpen Therapeutics from "In Line" to "Outperform." The company focused on the CTX320 and CTX310 in vivo gene editing initiatives, giving respectively 10% and 5% success rates. Second quarter of 2025 data from CTX320 is anticipated to line up with Novartis's cardiovascular outcomes study. Mid-2025 should provide updates on CTX112 (CAR-T treatment), CTX131 (oncology), and CTX221 (type 1 diabetes). Warning! GuruFocus has detected 4 Warning Signs with CRSP. From $1.7 billion at the end of 2023, the corporation said in December 31, 2024, $1.9 billion in cash, cash equivalents, and marketable securities. Compared with 40 at the end of October, the Casgevy cell collection program also grew with over 50 fresh collections in the last nine weeks of the fourth quarter. Although the firm's risk-adjusted model puts in low success probability for its new in vivo activities, its financial situation and clinical advancements indicate a better picture. This article first appeared on GuruFocus.
Reuters
27-01-2025
- Business
- Reuters
Akero soars as drug shows it reverses scarring in liver disease patients
Jan 27 (Reuters) - Akero Therapeutics (AKRO.O), opens new tab shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening the condition in a keenly awaited mid-stage trial. The experimental drug efruxifermin is being studied in patients with severe scarring or cirrhosis due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). In the trial, 39% of patients treated with a 50 milligram dose of the drug experienced reversal of cirrhosis with no worsening of MASH, compared with 15% of those who received a placebo, after 96 weeks. "Akero is the first to show reversal of cirrhosis, a goal that has evaded the field until now," said Evercore ISI analyst Liisa Bayko, calling the data "transformational". MASH, which was earlier known as NASH or non-alcoholic steatohepatitis, affects around 5% of adults in the U.S., according to the American Liver Foundation, making it a large patient population. Madrigal Pharmaceuticals' (MDGL.O), opens new tab, Rezdiffra, the only approved drug, treats patients with moderate to advanced liver scarring or fibrosis without cirrhosis. At least two analysts said Akero's drug could potentially be a multibillion-dollar opportunity for treating patients with cirrhosis who are the most severe and have the highest unmet need. Shares of peer 89bio (ETNB.O), opens new tab rose more than 60% after the study results. The company is conducting trials with its experimental drug pegozafermin in patients with severe scarring of the liver. Drugmakers such as Novo Nordisk ( opens new tab and Eli Lilly (LLY.N), opens new tab are also conducting trials with their blockbuster GLP-1 treatments to treat patients with the type of liver disease. In patients who were not taking GLP-1s, 45% of those who were on Akero's drug showed reversal of cirrhosis without worsening the condition, compared with 17% for placebo, which suggests the observed reversal was not attributable to GLP-1 therapy, the company said.
